Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Evaluation System of Bridging Study in Taiwan Chien-Hua Wu Statistical Reviewer at CDE Oct. 2, 2002 The views expressed in this presentation are not necessary those of Center for Drug Evaluation in Taiwan 77 Announcement • On July 7th 1993, 40 evaluable patients was required for registration in Taiwan • Receive the marketing exclusivity for 5 years 1212 Announcement • Due to world trade barrier for 77 Announcement • Bridging study was proposed on Dec. 12th, 2000 • Transitional period from 2000 to 2003, sponsor have choice to conduct either 40-evalauble patients or bridging study • Bridging study will be completely required after Jan. 1, 2004 • But no marketing exclusivity for bridging study Evaluation Process Sponsor • Bridging data package • Summary of selfevaluation BPA Checking list Consultants Supplemental documents Bridging Study not required Bridging Study required CDE acceptance Internal review meeting sponsor meeting Drug review committee Accessing the Requirement of a Bridging Study Does the drug meet DOH announcements for waiving a bridging study and the requirements of submitting ethnic insensitivity data? Yes No Submit relevant documents according to DOH announcements and request for waiving bridging studies Yes Does the package include clinical data of Asian populations*? Does the submitted preclinical and clinical data package meet the regulatory requirements? No Submit additional relevant information Does the package include clinical data of Asian populations*? Yes No Have any early phase or global clinical trials that meet the DOH requirements of bridging studies been conducted in Taiwan? Is the medicine sensitive to both intrinsic and extrinsic factors? Are the clinical differences in efficacy and safety significant? Yes Yes Bridging study required Is the result acceptable as a bridging study? Yes No bridging study required** No No Is it reasonable to extrapolate from foreign clinical data that the medicine is insensitive to both intrinsic and extrinsic factors in Asians and that its clinical differences in efficacy and safety are acceptable? (See ICH E5 guidelines) No No bridging study required Is it reasonable to extrapolate from foreign clinical data that the medicine is insensitive to both intrinsic and extrinsic factors in Asians and that its clinical differences in efficacy and safety are acceptable? Yes No bridging study required No Is it reasonable to extrapolate from foreign clinical data that the concentration (dose)-response relationship is similar between foreign and Asian populations ? No Yes No bridging study required Are PK and/or PD data of Asian populations available for dosage adjustment or efficacy/safety predication? Yes Available data will be used directly to estimate the proper dosage for Chinese populations. No Bridging study required CDE Bridging Study Evaluation Items (1) 1. 2. 3. 4. Linearity PK profile Steep PD profile Narrow therapeutic dose range Highly metabolized through a single pathway, potential drug-drug interaction 5. Genetic polymorphism (e.g. CYP2D6, CYP2C19, etc.) 6. Administration as a prodrug. 7. High inter-subject variation in biovailability CDE Bridging Study Evaluation Items (2) 8. Low bioavailability, susceptible dietary absorption effect 9. High likelihood of use in a setting of multiple co-medications 10. High likelihood for inappropriate use 11. Different indications and/or epidemiology 12. Other important factors of ethnic sensitivity (e.g. medical practice) Results of BS Evaluation from Jan. 1, 2001 to July 31, 2002 I 26 Case evaluated (40) II 14 I 18 (69%) BS waived (29)(73%) II I: With Asian data; II: Without Asian data 11 (79%) Statistical Approaches of Bridging Study Chien-Hua Wu Assistant Professor National Taipei University Oct. 2, 2002 Outline • Weakness of Evaluation System in CDE • Strategy for Bridging Study • Statistical Approaches to Detect the Ethnic Sensitivity • Dose Adjustment • Sample Size Reduction Bridging Study Evaluation in Taiwan (1) • “Assessment of the extrapolation of foreign clinical data for registration purposes” published by Lin et. al. in Drug Information Journal (2002) Bridging Study Evaluation in Taiwan (2) Bridging Study Evaluation in Taiwan (3) • 7 of 20 cases considered ethnic difference between original country and Taiwan in 2001 • 5 of 7 cases were related to safety issues • 2 cases due to lack of sufficient data to support efficacy in original country • Conclusion: it seems like using PK/PD profile may not be able to tell the ethnic sensitivity in some circumstance CDE Bridging Study Evaluation Items (1) 1. 2. 3. 4. Linearity PK profile Steep PD profile Narrow therapeutic dose range Highly metabolized through a single pathway, potential drug-drug interaction 5. High inter-subject variation in biovailability CDE Bridging Study Evaluation Items (2) 8. Low bioavailability, susceptible dietary absorption effect 9. High likelihood of use in a setting of multiple co-medications 10. High likelihood for inappropriate use 11. Different indications and/or epidemiology 12. Other important factors of ethnic sensitivity (e.g. medical practice) Weakness of Evaluation System in CDE • If 1st item fails but not for the rest of it, can we conclude that there is an ethnic difference??? • PK/PD profile may not be able to judge the ethnic difference if few evaluated items do not fit well • According ICH E5, the acceptability of foreign data should be evaluated based on similarity of dose response, efficacy and safety between foreign and new region Strategy for Bridging Study Step 1: Detect ethnic sensitivity by looking at the PK/PD evaluation items and using statistical approaches Step 2: No need to conduct a bridging trial if there is no sufficient evidence to tell the ethnic difference between original region and local region Step 3: Adjust dose if ethnic difference does exist Step 4: Conduct a bridging trial to show efficacy in the local region using new dose Statistical Approaches to Detect Ethnic Sensitivity 1. Check treatment by region interaction 2. Reproducibility and generalizability probability (Shao and Chow (2002)) 3. Conduct a non-inferiority or equivalent trial 4. Conduct a local trial for 40 evaluable patients (Baysian approach) 5. Conduct a multinational trial 1st Statistical Approach: Treatment by Region Interaction • H0: No Interaction • Fail to reject the interaction does not mean there are no differences between two regions. • HA: Treatment effect is different between two regions • Magnitude of difference is of any clinical relevance? Sufficient sample size? • See Comments from ICSA (2002) 2nd Statistical Approach: Reproducibility Probability • “Reproducibility probability in clinical trials” by Shao J. and Chow S.C. (2002) Reproducibility Probability • H0: 1-2=0 • Power of test statistic: function of =(12)/(1/n1+1/n2)(1/2) • Replace parameter by its estimate T(x) • Reproducibility probability: estimated power Evaluation Process for Bridging Study Step 1: If the reproducibility probability fails to meet regulatory requirement of reproducibility, say >80%, then bridging study is not needed. Step 2: Measure the signal-to-noise for population difference Step 3: Compute the generalizability probability Generalizability Probability • When the study drug product is applied to a similar but different patient population in the new region, it is expected that the mean and variance of response will be different. • Population mean difference change to 1- 2+ • Population variance change to C2 2 • Measure of change in signal-to-noise for population difference: ={1+/(1- 2)}/C • Generalizability probability: replace in power by T(x) Recommendation Based on Generalizability Probability Example • A schizophrenia study • 104 patients: 56 patients using new treatment and 48 patients for standard therapy • T=-2.88 and p-value=0.004 • Reproducibility probability=0.814 > 80%, thus a bridging trial is required • =0.9 and desired power=80%, then n=118 Generalizability Probability and Sample Size Requirement Comments on Reproducibility and Generalizability Probability • Regulatory requirement of reproducibility and generalizability probability are subjective. • Need to know the population mean and variance for new region • Sample size of the bridging trial is larger than that of original trial if <1 • Fail to address the similarity between the new and original regions required by ICH E5 (Liu, et. at. 2002) 3rd Statistical Approach: Noninferiority or Equivalent Trial (1) • “Sample size requirement for evaluation of bridging evidence” by Liu, et. al. (2002) Non-inferiority or Equivalent Trial (2) • Definition of Similarity: no substantial difference (equivalence) • Purpose: issue on sample size in planning bridging study and evaluation of similarity • Hierarchical model: trials have been conducted for the approval of the drug product in original region and a bridging trial is being conducted in a new region for registration after the approval in the original region Example Non-inferiority or Equivalent Trial (4) • What is the definition of similarity stated in ICH E5? • How to choose the margin? • Comments in ICSA (2002) • Controversial selection of equivalence limit (Temple and Ellenberg (2000), Ellenber and Temple (2000), Fisher et al. (2001), Hung (2001), Snappin (2001), Tsong, et. al. (2001), Wittes (2001) th 4 Statistical Approach: Baysian Approach (1) • Proposed by Shih in 2001 in Controlled Clinical Trials Baysian Approach (2) • k study centers • wi stands for test statistic i=1,…,k • wi approximately follows N(μ,1) for large sample size • Predictive probability density function can be obtained with vague prior for μ • New trial is consistent with reference studies if p(v|w)>min{p(wi|W), i=1,…,k} Comments on Baysian Approach (3) • Correction is needed for small sample in a particular center • More reference studies, greater chance to be consistent 5th Statistical Approach: Multinational Trial (1) Spilker in 1991 outlined the motivations of conducting a multinational trial 1. Gaining more rapid patient enrollment 2. Expediting the development of a new medicine 3. Conducting a trial that otherwise might be impossible 4. Gaining experience and being able to compare patients of different nationalities Takeuchi (2002) also raise the issues of the importance in global drug development Multinational Trial (2) • • • • • H0: 1-2=0 Ti represents for the test statistic where i=1,…,r Tl represents for the test statistic for local region Goal: check Tl to see if it is an outlier (not similar). If it exists, then the ethnic difference is appeared. -4 -2 0 2 x 4 0.0 0.1 0.2 density 0.3 0.4 If Ethnic Difference Exists • A clinical trial is essentially required to prove the effectiveness of study drug in the local region (adjust the dose if needed) • ICH E5: avoid unnecessary repetition of costly and time-consuming clinical trials (sample size reduction) Dose Adjustment Asian Caucasian AUC or Cmax Dose Sample Size Reduction • “Sample Size Reduction in Bridging Study Using Regression Estimator” by Wu et. al. (2001) Sample Size Reduction (2) Sample Size Reduction (3) Sample Size Reduction (4) • Means, S.D. and slope need to know from previous study in order to calculate the sample size • Interim analysis may be needed to reestimate means, S.D. and slope Example • • • • • Acute Asthma study Primary endpoint: FEV1 Compare study drug and placebo Mean difference: 0.10 L S.D.=0.31 Conclusions • Under process to develop the statistical approaches in CDE to detect the ethnic sensitivity other than assessing PK/PD profile • Dose adjustment may be needed if ethnic difference does exist • Reducing sample size is considered if a bridging trial is needed